Swedish English Contact Us BioInvent Menu About BioInvent Business Strategy Management Team Board of Directors Scientific Advisory Board Corporate Citizenship Careers Projects Haematological Cancer Oncology BI-1206 TB-403 THR-317 Preclinical Projects Pipeline Clinical Trials Market Overview Partners Scientific collaborations Presentation of partnerships Partner's Projects Commercial contact Science n-CoDeR® F.I.R.S.T.™ Manufacturing Biological and Preclinical Expertise Scientific publications Investors Share Price Financial Reports Press Releases Presentations Investor Information New share issue 2016 Corporate Governance Investor Contact Subscription Service Media Centre Press Releases Scientific publications Events Downloads BioInvent is a research-based pharmaceutical company focused on the discovery and development of innovative antibody-based drugs against cancer. F.I.R.S.T.™ is a novel and unique patented target discovery technology which allows for antibodies and disease targets to be identified simultaneously. We discover and develop innovative antibody-based drugs for the treatment of cancer. F.I.R.S.T.™ is a novel and unique patented target discovery technology which allows for antibodies and disease targets to be identified simultaneously. OUR PIPELINE BioInvent has two active projects in clinical development. BI-1206 – non-Hodgkin-lymphoma TB-403 – medulloblastoma In addition, BioInvent has a number of research stage projects that we consider promising; especially in the field of immuno-oncology. READ MORE Business Focus BioInvent is generating value for shareholders by employing its antibody and cancer biology expertise to identify antibodies with novel mechanisms-of-action and novel oncology targets. The Company employs this approach to generate therapeutic immuno-modulating antibodies that can be developed for a broad range of cancer indications. The Company plans to bring these antibodies to the clinic through its own resources and together with partners. READ MORE Press Releases MEET US Sep 25-28, 2017, BioProcess International, Boston, USA Sep 26-27, 2017, BioPharm America, Boston, USA Oct 31-Nov 2, 2017, European Antibody Congress, Basel, Switzerland SCIENTIFIC ADVISORY BOARD ESTABLISHED >>READ MORE SEK Bid Ask High Low Volume Turnover Updated About BioInvent Business Strategy Management Team Board of Directors Scientific Advisory Board Corporate Citizenship Careers Projects Haematological Cancer Oncology BI-1206 TB-403 THR-317 Preclinical Projects Pipeline Clinical Trials Market Overview Partners Scientific collaborations Presentation of partnerships Partner's Projects Commercial contact Science n-CoDeR® F.I.R.S.T.™ Manufacturing Biological and Preclinical Expertise Scientific publications Investors Share Price Financial Reports Press Releases Presentations Investor Information New share issue 2016 Corporate Governance Investor Contact Subscription Service Media Centre Press Releases Scientific publications Events Downloads CONTACT US LEGAL DISCLAIMER Copyright © BioInvent International AB